Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Maria Rodriguez Santiago

Cardiovascular Disease Guaynabo, PR Medical Doctor

NPI 1053852962 CMS profile 8133998

101 Ave San Patricio, Ste 1260, Guaynabo, PR 00968

Open in the dashboard

General payments

$2,670

85 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Rodriguez Santiago of Guaynabo, PR is reported in the CMS Open Payments database as having received $2,670 across 85 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $359 17
2024 General $788 27
2023 General $542 17
2022 General $715 20
2021 General $267 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Rodriguez Santiago
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Maria Rodriguez Santiago were reported at $359. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Maria Rodriguez Santiago Cardiovascular Disease median Middle half National median
2019 $0 $450 $127–$1,392 $163
2020 $0 $242 $77–$751 $114
2021 $267 $335 $101–$1,037 $132
2022 $715 $395 $121–$1,211 $149
2023 $542 $443 $136–$1,283 $160
2024 $788 $450 $136–$1,323 $164
2025 $359 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $824 32 payments
  2. Boston Scientific Corporation $569 5 payments
  3. PBG Puerto Rico LLC $246 12 payments
  4. AstraZeneca Pharmaceuticals LP $197 5 payments
  5. Medtronic, Inc. $155 1 payment
  6. E.R. Squibb & Sons, L.L.C. $125 7 payments
  7. Novartis Pharmaceuticals Corporation $119 6 payments
  8. Abbott Laboratories $110 1 payment
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $62 3 payments
  10. Bayer Puerto Rico Inc. $48 2 payments
  11. Other $215 11 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,450 84 payments
  2. Education $220 1 payment
Products named General payments · program years 2021–2025
  1. LifeVest $824 32 payments
  2. General - Tachy $363 3 payments
  3. ELIQUIS $170 8 payments
  4. ONYX FRONTIER $155 1 payment
  5. FARXIGA $137 2 payments
  6. ACCOLADE SR $125 1 payment
  7. CAMZYOS $112 6 payments
  8. GALLANT $110 1 payment
  9. LEQVIO $102 5 payments
  10. VYNDAQEL $92 5 payments
  11. Other $514 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

278

Median for Internal Medicine: 777

Drug cost

$49,687

Median for Internal Medicine: $73,373

Branded share of claims

34.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 38 $24,480
Entresto Sacubitril/Valsartan Brand 14 $9,641
Xarelto Rivaroxaban Brand 11 $7,347
Eliquis Apixaban Brand 11 $6,345
Synthroid Levothyroxine Sodium Brand 12 $586
Metoprolol Succinate Generic 28 $301
Spironolactone Generic 33 $267
Atorvastatin Calcium Generic 33 $245
Carvedilol Generic 35 $168
Rosuvastatin Calcium Generic 17 $103

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
  • Novartis Pharmaceuticals Corporation $82
$82 — —
ELIQUIS
  • PBG PUERTO RICO LLC $73
$73 11 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $62
$62 38 —
LOKELMA
  • AstraZeneca Pharmaceuticals LP $35
$35 — —
VYNDAQEL
  • PBG PUERTO RICO LLC $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

85 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record